Replies to post #25934 on Mymetics Corp (MYMX)

[bow-tie]

Vaccination is the most effective means of controlling infectious disease-related morbidity and mortality.
However, due to low immunogenicity of viral antigens, nanomedicine as a new opportunity in new generation
of vaccine advancement attracted researcher encouragement. Virosome is a lipidic nanomaterial emerging as
FDA approved nanocarriers with promising bioinspiration and biomimetic potency against viral infections.
Virosome surface modification with critical viral fusion proteins is the cornerstone of vaccine development.
Surface antigens at virosomes innovatively interact with targeted receptors on host cells that evoke humoral
or cellular immune responses through antibody-producing B cell and internalization by endocytosis-mediated
pathways. To date, several nanovaccine based on virosome formulations have been commercialized against
widespread and life-threatening infections. Recently, Great efforts were made to fabricate a virosome-based vaccine platform against a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Thus, this review provides a novel overview of the virosome based nanovaccine production, properties, and application on
the viral disease, especially its importance in SARS-CoV-2 vaccine discovery.
© 2021 Elsevier B.V. All rights reserved.
https://kb4.ingentium.com/scoutData/references/covkb/pdf/61487.pdf
https://covkb.ingentium.com/evidence/references/61752